Atlas Trials

A Study to Target the Type I IFN Receptor by Administrating Anifrolumab in RA Patients With a High IFN Signature (TarIFNiRA)

Clinical trial NCT03435601 · UNKNOWN

Trial details

NCT number
NCT03435601
Sponsor
Josef Smolen, Univ. Prof. Dr.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Rheumatoid Arthritis
Start date
2018-04-18
Primary completion
2021-03-01
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.